Clinical Scorecard: Prognostic Conversations on Staging Glioblastoma
At a Glance
Category
Detail
Condition
Glioblastoma (GBM), an incurable brain cancer
Key Mechanisms
Tumor growth causing cognitive decline and limited survival despite standard treatments
Target Population
Patients diagnosed with glioblastoma
Care Setting
Neuro-oncology clinics and multidisciplinary cancer care settings
Key Highlights
Median overall survival is 15–20 months with standard care; 8–9 months after recurrence.
Standard of care includes surgery, radiation with temozolomide, adjuvant temozolomide, and/or tumor treating fields.
Early prognostic discussions should include incurability, life expectancy, and impending cognitive decline.
Guideline-Based Recommendations
Diagnosis
Diagnose GBM using standard clinical and radiographic criteria.
Recognize GBM as incurable with guarded prognosis after recurrence.
Management
Provide standard of care: surgery, radiation with concurrent temozolomide, followed by adjuvant temozolomide (6–12 cycles).
Consider tumor treating fields as adjunct therapy.
Engage in early advance care planning due to anticipated cognitive decline.
Monitoring & Follow-up
Monitor neurologic function and cognitive status throughout disease course.
Assess patient understanding and preferences regularly to guide care.
Risks
Risk of cognitive decline leading to loss of decision-making capacity.
Potential for inconsistent or ineffective communication of prognosis.
Emotional distress related to prognostic disclosure impacting hope.
Patient & Prescribing Data
Patients with newly diagnosed and recurrent glioblastoma
Standard treatments prolong survival modestly; no new systemic therapies approved since 2009; treatment aims to preserve neurologic function and quality of life.
Clinical Best Practices
Disclose incurability and impending cognitive decline at first consultation with tact and emotional attunement.
Delay detailed life expectancy discussions to subsequent visits, individualized per patient preferences and clinical status.
Prioritize patient autonomy and informed consent through explicit prognostic disclosure.
Incorporate advance care planning early before cognitive decline impairs decision-making capacity.
Recognize and address barriers to prognostic communication including clinician fear of diminishing hope.
Use staged disclosure framework tailored to patient characteristics and disease trajectory.
